The fastest way to find out is to take our free, 5-minute intake survey
New England Journal of Medicine (2025) The REDEFINE 1 Phase 3 trial was a landmark 68-week, double-blind, randomized study comparing CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) with semaglutide alone, cagrilintide alone, and placebo in 3,417 adults with obesity or overweight without diabetes
:
It also lists a wide set of medication options, including GLP-1 receptor agonists and compounded formulations, plus automatic refill reminders
After 40 weeks, those type 2 diabetes patients who received 15 mg of tirzepatide had lost nearly 25 pounds while those who were receiving 1mg of semaglutide which is the standard dose led to weight loss of nearly 12.5 pounds
Because of this origin, it has drawn significant attention in studies examining both musculoskeletal recovery and gastrointestinal protection